Selvita S.A. (WSE: SLV)

Market Cap	1.04B
Revenue (ttm)	329.02M
Net Income (ttm)	47.40M
Shares Out	18.36M
EPS (ttm)	2.58
PE Ratio	22.00
Forward PE	30.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,982
Open	56.30
Previous Close	56.80
Day's Range	56.00 - 57.10
52-Week Range	55.40 - 73.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 25, 2024

About Selvita

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis. I...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 387
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SLV

Financial Performance

In 2023, Selvita's revenue was 351.85 million, a decrease of -3.48% compared to the previous year's 364.55 million. Earnings were 69.88 million, an increase of 130.55%.